Francesco Ortuso
Overview
Explore the profile of Francesco Ortuso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
1452
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maggisano V, Gargano A, Maiuolo J, Ortuso F, De Amicis F, Alcaro S, et al.
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39941053
Targeting the tumor microenvironment (TME) is an attractive strategy for developing new drugs with anticancer activity against triple-negative breast cancer (TNBC). Interleukins (ILs) are key players in the TME cytokine...
2.
Murdocca M, Romeo I, Citro G, Latini A, Centofanti F, Bugatti A, et al.
Pharmaceuticals (Basel)
. 2024 Jul;
17(7).
PMID: 39065742
Genomic surveillance based on sequencing the entire genetic code of SARS-CoV-2 involves monitoring and studying genetic changes and variations in disease-causing organisms such as viruses and bacteria. By tracing the...
3.
Lombardo L, Mirabile S, Gitto R, Cosentino G, Alcaro S, Dichiara M, et al.
J Chem Inf Model
. 2024 Jun;
64(14):5701-5711.
PMID: 38940754
Sigma-1 receptor (S1R) is involved in a large array of biological functions due to its ability to interact with various proteins and ion channels. Crystal structures of human S1R revealed...
4.
Panzarella G, Gallo A, Coecke S, Querci M, Ortuso F, Hofmann-Apitius M, et al.
Eur J Med Chem
. 2024 May;
273:116522.
PMID: 38801799
The growing number of scientific papers and document sources underscores the need for methods capable of evaluating the quality of publications. Researchers who are looking for relevant papers for their...
5.
Matos M, Novo P, Mayan L, Torres I, Uriarte E, Yanez M, et al.
Eur J Med Chem
. 2023 Jan;
248:115091.
PMID: 36638711
Psychiatric and neurological disorders affect millions of people worldwide. Currently available treatments may help to improve symptoms, but they cannot cure the diseases. Therefore, there is an urgent need for...
6.
Di Sanzo M, Cozzolino F, Battaglia A, Aversa I, Monaco V, Sacco A, et al.
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36361777
The H Ferritin subunit (FTH1), as well as regulating the homeostasis of intracellular iron, is involved in complex pathways that might promote or inhibit carcinogenesis. This function may be mediated...
7.
Reis J, Fernandes C, Salem H, Maia M, Tome C, Benfeito S, et al.
Eur J Med Chem
. 2022 Jun;
239:114507.
PMID: 35772321
The absence of disease modifying drugs in Parkinson's disease therapy urges for new chemical entities acting on relevant PD-associated biological targets. As a result, developing selective and reversible inhibitors targeting...
8.
Rocca R, Scionti F, Nadai M, Moraca F, Maruca A, Costa G, et al.
Pharmaceuticals (Basel)
. 2022 May;
15(5).
PMID: 35631373
In mammalian cells, telomerase transcribes telomeres in large G-rich non-coding RNA, known as telomeric repeat-containing RNA (TERRA), which folds into noncanonical nucleic acid secondary structures called G-quadruplexes (G4s). Since TERRA...
9.
Catalano R, Procopio F, Chavarria D, Benfeito S, Alcaro S, Borges F, et al.
Molecules
. 2022 Apr;
27(8).
PMID: 35458667
Human monoamine oxidases (MAOs) are well-established targets for the treatment of neurological disorders such as depression, Parkinson's disease and Alzheimer's disease. Despite the efforts carried out over the years, few...
10.
Catalano R, Maruca A, Rocca R, Tassone P, Panzarella G, Costa G, et al.
Future Med Chem
. 2022 Mar;
14(9):609-621.
PMID: 35348013
The inhibition of PRC2, implicated in the pathogenesis of several tumors, can be a useful therapeutic strategy for cancer treatment. In the literature, two types of PRC2 modulators are reported:...